Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
@prefix fhir: <http://hl7.org/fhir/> . @prefix owl: <http://www.w3.org/2002/07/owl#> . @prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> . @prefix xsd: <http://www.w3.org/2001/XMLSchema#> . # - resource ------------------------------------------------------------------- a fhir:Bundle ; fhir:nodeRole fhir:treeRoot ; fhir:id [ fhir:v "bundlepackageleaflet-en-008c725c88c429f9cddb37027a290218"] ; # fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"^^xsd:anyURI ; fhir:link <http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi> ] ) ] ; # fhir:language [ fhir:v "en"] ; # fhir:identifier [ fhir:system [ fhir:v "http://ema.europa.eu/identifier"^^xsd:anyURI ] ; fhir:value [ fhir:v "None" ] ] ; # fhir:type [ fhir:v "document"] ; # fhir:timestamp [ fhir:v "2023-06-27T10:09:22Z"^^xsd:dateTime] ; # fhir:entry ( [ fhir:fullUrl [ fhir:v "Composition/composition-en-008c725c88c429f9cddb37027a290218"^^xsd:anyURI ] ; ( fhir:resource <Composition/composition-en-008c725c88c429f9cddb37027a290218> ) ] [ fhir:fullUrl [ fhir:v "MedicinalProductDefinition/mp008c725c88c429f9cddb37027a290218"^^xsd:anyURI ] ; ( fhir:resource <MedicinalProductDefinition/mp008c725c88c429f9cddb37027a290218> ) ] ) . # <Composition/composition-en-008c725c88c429f9cddb37027a290218> a fhir:Composition ; fhir:id [ fhir:v "composition-en-008c725c88c429f9cddb37027a290218"] ; # fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"^^xsd:anyURI ; fhir:link <http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi> ] ) ] ; # fhir:language [ fhir:v "en"] ; # fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-008c725c88c429f9cddb37027a290218\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-008c725c88c429f9cddb37027a290218</b></p><a name=\"composition-en-008c725c88c429f9cddb37027a290218\"> </a><a name=\"hccomposition-en-008c725c88c429f9cddb37027a290218\"> </a><a name=\"composition-en-008c725c88c429f9cddb37027a290218-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/17/1178/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - xeljanz</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>" ] ; # fhir:identifier ( [ fhir:system [ fhir:v "http://ema.europa.eu/identifier"^^xsd:anyURI ] ; fhir:value [ fhir:v "EU/1/17/1178/001" ] ] ) ; # fhir:status [ fhir:v "final"] ; # fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "Package Leaflet" ] ] ; # fhir:category ( [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"^^xsd:anyURI ] ; fhir:code [ fhir:v "R" ] ; fhir:display [ fhir:v "Raw" ] ] ) ] ) ; # fhir:subject ( [ fhir:reference [ fhir:v "MedicinalProductDefinition/mp008c725c88c429f9cddb37027a290218" ] ] ) ; # fhir:date [ fhir:v "2022-02-16T13:28:17Z"^^xsd:dateTime] ; # fhir:author ( [ fhir:reference [ fhir:v "Organization/mah-ema" ] ] ) ; # fhir:title [ fhir:v "TEST PURPOSES ONLY - xeljanz"] ; # fhir:attester ( [ fhir:mode [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/composition-attestation-mode"^^xsd:anyURI ] ; fhir:code [ fhir:v "official" ] ] ) ] ; fhir:time [ fhir:v "2022-02-16T13:28:17Z"^^xsd:dateTime ] ] ) ; # fhir:section ( [ fhir:title [ fhir:v "B. Package Leaflet" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "B. Package Leaflet" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>" ] ; fhir:emptyReason [ ( fhir:coding [ fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/list-empty-reason"^^xsd:anyURI ] ; fhir:code [ fhir:v "unavailable" ] ] ) ] ; ( fhir:section [ fhir:title [ fhir:v "Package leaflet: Information for the user" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "Package leaflet: Information for the user" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>" ] ] [ fhir:title [ fhir:v "What is in this leaflet" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "What is in this leaflet" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What XELJANZ is and what it is used for</li><li>What you need to know before you take XELJANZ</li><li>How to take XELJANZ</li><li>Possible side effects</li><li>How to store XELJANZ</li><li>Contents of the pack and other information</li></ol></div>" ] ] [ fhir:title [ fhir:v "1. What xeljanz is and what it is used for" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "1. What xeljanz is and what it is used for" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>XELJANZ is a medicine that contains the active substance tofacitinib. XELJANZ is used for the treatment of the following inflammatory diseases:</p><p>rheumatoid arthritis</p><p>psoriatic arthritis</p><p>ulcerative colitis</p><p>ankylosing spondylitis</p><p>polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis Rheumatoid arthritis XELJANZ is used to treat adult patients with moderate to severe active rheumatoid arthritis, a long-term disease that mainly causes pain and swelling of your joints. XELJANZ is used together with methotrexate when previous rheumatoid arthritis treatment was not sufficient or was not well tolerated. XELJANZ can also be taken on its own in those cases where methotrexate treatment is not tolerated or treatment with methotrexate is not advised. XELJANZ has been shown to reduce pain and swelling of the joints and improve the ability to perform daily activities, when given on its own or together with methotrexate. Psoriatic arthritis XELJANZ is used to treat adult patients with a condition called psoriatic arthritis. This condition is an inflammatory disease of the joints, often accompanied by psoriasis. If you have active psoriatic arthritis you will be first given another medicine to treat your psoriatic arthritis. If you do not respond well enough or the medicine is not tolerated, you may be given XELJANZ to reduce the sign and symptoms of active psoriatic arthritis and improve the ability to perform daily activities. XELJANZ is used together with methotrexate to treat adult patients with active psoriatic arthritis. Ankylosing spondylitis XELJANZ is used to treat a condition called ankylosing spondylitis. This condition is an inflammatory disease of the spine. If you have ankylosing spondylitis, you may first be given other medicines. If you do not respond well enough to these medicines, you will be given XELJANZ. XELJANZ can help to reduce back pain, and improve physical function. These effects can ease your normal daily activities and so improve your quality of life. Ulcerative colitis Ulcerative colitis is an inflammatory disease of the large bowel. XELJANZ is used in adult patients to reduce the signs and symptoms of ulcerative colitis when you did not respond well enough or were intolerant to previous ulcerative colitis treatment. Polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis XELJANZ is used for the treatment of active polyarticular juvenile idiopathic arthritis a long-term disease that mainly causes pain and swelling of your joints, in patients 2 years of age and older. XELJANZ is also used for the treatment of juvenile psoriatic arthritis, a condition that is an inflammatory disease of the joints often accompanied by psoriasis, in patients 2 years of age and older. XELJANZ can be used together with methotrexate when previous treatment for polyarticular juvenile idiopathic arthritis or juvenile psoriatic arthritis was not sufficient or was not well tolerated. XELJANZ can also be taken on its own in those cases where methotrexate treatment is not tolerated or treatment with methotrexate is not advised.</p></div>" ] ] [ fhir:title [ fhir:v "2. What you need to know before you take xeljanz" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "2. What you need to know before you take xeljanz" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><h2 id=\"do-not-take-xeljanz\">Do not take XELJANZ</h2><h2 id=\"if-you-are-allergic-to-tofacitinib-or-any-of-the-other-ingredients-of-this-medicine-listed-in-section-6\">if you are allergic to tofacitinib or any of the other ingredients of this medicine (listed in section 6)</h2><h2 id=\"if-you-have-a-severe-infection-such-as-bloodstream-infection-or-active-tuberculosis\">if you have a severe infection such as bloodstream infection or active tuberculosis</h2><h2 id=\"if-you-have-been-informed-that-you-have-severe-liver-problems-including-cirrhosis-scarring-of-the-liver\">if you have been informed that you have severe liver problems, including cirrhosis (scarring of the liver)</h2><h2 id=\"if-you-are-pregnant-or-breast-feeding-if-you-are-not-sure-regarding-any-of-the-information-provided-above-please-contact-your-doctor-warnings-and-precautions-talk-to-your-doctor-or-pharmacist-before-taking-xeljanz\">if you are pregnant or breast-feeding If you are not sure regarding any of the information provided above, please contact your doctor. Warnings and precautions Talk to your doctor or pharmacist before taking XELJANZ:</h2><h2 id=\"if-you-think-you-have-an-infection-or-have-symptoms-of-an-infection-such-as-fever-sweating-chills-muscle-aches-cough-shortness-of-breath-new-phlegm-or-change-in-phlegm-weight-loss-warm-or-red-or-painful-skin-or-sores-on-your-body-difficulty-or-pain-when-swallowing-diarrhoea-or-stomach-pain-burning-when-you-urinate-or-urinating-more-often-than-normal-feeling-very-tired\">if you think you have an infection or have symptoms of an infection such as fever, sweating, chills, muscle aches, cough, shortness of breath, new phlegm or change in phlegm, weight loss, warm or red or painful skin or sores on your body, difficulty or pain when swallowing, diarrhoea or stomach pain, burning when you urinate or urinating more often than normal, feeling very tired</h2><h2 id=\"if-you-have-any-condition-that-increases-your-chance-of-infection-eg-diabetes-hivaids-or-a-weak-immune-system\">if you have any condition that increases your chance of infection (e.g., diabetes, HIV/AIDS, or a weak immune system)</h2><h2 id=\"if-you-have-any-kind-of-infection-are-being-treated-for-any-infection-or-if-you-have-infections-that-keep-coming-back-tell-your-doctor-immediately-if-you-feel-unwell-xeljanz-can-reduce-your-body-s-ability-to-respond-to-infections-and-may-make-an-existing-infection-worse-or-increase-the-chance-of-getting-a-new-infection\">if you have any kind of infection, are being treated for any infection, or if you have infections that keep coming back. Tell your doctor immediately if you feel unwell. XELJANZ can reduce your body s ability to respond to infections and may make an existing infection worse or increase the chance of getting a new infection</h2><h2 id=\"if-you-have-or-have-a-history-of-tuberculosis-or-have-been-in-close-contact-with-someone-with-tuberculosis-your-doctor-will-test-you-for-tuberculosis-before-starting-xeljanz-and-may-retest-during-treatment\">if you have or have a history of tuberculosis or have been in close contact with someone with tuberculosis. Your doctor will test you for tuberculosis before starting XELJANZ and may retest during treatment</h2><h2 id=\"if-you-have-any-chronic-lung-disease\">if you have any chronic lung disease</h2><h2 id=\"if-you-have-liver-problems\">if you have liver problems</h2><h2 id=\"if-you-have-or-had-hepatitis-b-or-hepatitis-c-viruses-that-affect-the-liver-the-virus-may-become-active-while-you-are-taking-xeljanz-your-doctor-may-do-blood-tests-for-hepatitis-before-you-start-treatment-with-xeljanz-and-while-you-are-taking-xeljanz\">if you have or had hepatitis B or hepatitis C (viruses that affect the liver). The virus may become active while you are taking XELJANZ. Your doctor may do blood tests for hepatitis before you start treatment with XELJANZ and while you are taking XELJANZ</h2><h2 id=\"if-you-are-65-years-of-age-and-older-if-you-have-ever-had-any-type-of-cancer-and-also-if-you-are-a-current-or-past-smoker-xeljanz-may-increase-your-risk-of-certain-cancers-white-blood-cell-cancer-lung-cancer-and-other-cancers-such-as-breast-skin-prostate-and-pancreatic-have-been-reported-in-patients-treated-with-xeljanz-if-you-develop-cancer-while-taking-xeljanz-your-doctor-will-review-whether-to-stop-xeljanz-treatment\">if you are 65 years of age and older, if you have ever had any type of cancer, and also if you are a current or past smoker. XELJANZ may increase your risk of certain cancers. White blood cell cancer, lung cancer and other cancers (such as breast, skin, prostate and pancreatic) have been reported in patients treated with XELJANZ. If you develop cancer while taking XELJANZ your doctor will review whether to stop XELJANZ treatment.</h2><h2 id=\"if-you-are-at-known-risk-of-fractures-eg-if-you-are-65-years-of-age-and-older-you-are-a-female-or-take-corticosteroids-eg-prednisone\">if you are at known risk of fractures, e.g., if you are 65 years of age and older, you are a female, or take corticosteroids (e.g., prednisone).</h2><h2 id=\"cases-of-non-melanoma-skin-cancer-have-been-observed-in-patients-taking-xeljanz-your-doctor-may-recommend-that-you-have-regular-skin-examinations-while-taking-xeljanz-if-new-skin-lesions-appear-during-or-after-therapy-or-if-existing-lesions-change-appearance-tell-your-doctor\">Cases of non-melanoma skin cancer have been observed in patients taking XELJANZ. Your doctor may recommend that you have regular skin examinations while taking XELJANZ. If new skin lesions appear during or after therapy or if existing lesions change appearance, tell your doctor.</h2><h2 id=\"if-you-have-had-diverticulitis-a-type-of-inflammation-of-the-large-intestine-or-ulcers-in-stomach-or-intestines-see-section-4\">if you have had diverticulitis (a type of inflammation of the large intestine) or ulcers in stomach or intestines (see section 4)</h2><h2 id=\"if-you-have-kidney-problems\">if you have kidney problems</h2><h2 id=\"if-you-are-planning-to-get-vaccinated-tell-your-doctor-certain-types-of-vaccines-should-not-be-given-when-taking-xeljanz-before-you-start-xeljanz-you-should-be-up-to-date-with-all-recommended-vaccinations-your-doctor-will-decide-whether-you-need-to-have-herpes-zoster-vaccination\">if you are planning to get vaccinated, tell your doctor. Certain types of vaccines should not be given when taking XELJANZ. Before you start XELJANZ, you should be up to date with all recommended vaccinations. Your doctor will decide whether you need to have herpes zoster vaccination.</h2><p>if you have heart problems, high blood pressure, high cholesterol, and also if you are a current or past smoker There have been reports of patients treated with XELJANZ who have developed blood clots in the lungs or veins. Your doctor will evaluate your risk to develop blood clots in the lungs or veins and determine if XELJANZ is appropriate for you. If you have already had problems on developing blood clots in lungs and veins or have an increased risk for developing this (for example: if you are seriously overweight, if you have cancer, heart problems, diabetes, experienced a heart attack (within previous 3 months), recent major surgery, if you use hormonal contraceptives\\hormonal replacement therapy, if a coagulation defect is identified in you or your close relatives), if you are of older age, or if you smoke currently or in the past, your doctor may decide that XELJANZ is not suitable for you. Talk to your doctor straight away if you develop sudden shortness of breath or difficulty breathing, chest pain or pain in upper back, swelling of the leg or arm, leg pain or tenderness, or redness or discoloration in the leg or arm while taking XELJANZ, as these may be signs of a clot in the lungs or veins. Talk to your doctor straight away if you experience acute changes to your eyesight (blurry vision, partial or complete loss of vision), as this may be a sign of blood clots in the eyes. There have been reports of patients treated with XELJANZ who have had a heart problem, including heart attack. Your doctor will evaluate your risk to develop a heart problem and determine if XELJANZ is appropriate for you. Talk to your doctor straight away if you develop signs and symptoms of a heart attack including severe chest pain or tightness (that may spread to arms, jaw, neck, back), shortness of breath, cold sweat, light headedness or sudden dizziness. Additional monitoring tests Your doctor should perform blood tests before you start taking XELJANZ, and after 4 to 8 weeks of treatment and then every 3 months, to determine if you have a low white blood cell (neutrophil or lymphocyte) count, or a low red blood cell count (anaemia). You should not receive XELJANZ if your white blood cell (neutrophil or lymphocyte) count or red blood cell count is too low. If needed, your doctor may interrupt your XELJANZ treatment to reduce the risk of infection (white blood cell counts) or anaemia (red blood cell counts). Your doctor may also perform other tests, for example to check your blood cholesterol levels or monitor the health of your liver. Your doctor should test your cholesterol levels 8 weeks after you start receiving XELJANZ. Your doctor should perform liver tests periodically. Elderly There is a higher rate of infections, some of which may be serious, in patients 65 years of age and older. Tell your doctor as soon as you notice any signs or symptoms of infections. Patients 65 years of age and older may be at increased risk of infections, heart attack and some types of cancer. Your doctor may decide that XELJANZ is not suitable for you. Asian patients There is a higher rate of shingles in Japanese and Korean patients. Tell your doctor if you notice any painful blisters on your skin. You may also be at higher risk of certain lung problems. Tell your doctor if you notice any breathing difficulties. Children and adolescents The safety and benefits of XELJANZ in children have not yet been established in patients less than 2 years of age. Other medicines and XELJANZ Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Tell your doctor if you have diabetes or are taking medicines to treat diabetes. Your doctor may decide if you need less anti-diabetic medicine while taking tofacitinib. Some medicines should not be taken with XELJANZ. If taken with XELJANZ, they could alter the level of XELJANZ in your body, and the dose of XELJANZ may require adjustment. You should tell your doctor if you are using medicines that contain any of the following active substances:</p><p>antibiotics such as rifampicin, used to treat bacterial infections</p><p>fluconazole, ketoconazole, used to treat fungal infections XELJANZ is not recommended for use with medicines that depress the immune system, including so-called targeted biologic (antibody) therapies, such as those that inhibit tumour necrosis factor, interleukin-17, interleukin-12/interleukin-23, anti-integrins, and strong chemical immunosuppressants including azathioprine, mercaptopurine, ciclosporin, and tacrolimus. Taking XELJANZ with these medicines may increase your risk of side effects including infection. Serious infections and fractures may happen more often in people who also take corticosteroids (e.g., prednisone). Pregnancy and breast-feeding If you are a woman of childbearing age, you should use effective birth control during treatment with XELJANZ and for at least 4 weeks after the last dose. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. XELJANZ must not be used during pregnancy. Tell your doctor right away if you become pregnant while taking XELJANZ. If you are taking XELJANZ and breast-feeding, you must stop breast-feeding until you talk to your doctor about stopping treatment with XELJANZ. Driving and using machines XELJANZ has no or limited effect on your ability to drive or use machines. XELJANZ contains lactose If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. XELJANZ contains sodium This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium-free .</p></div>" ] ] [ fhir:title [ fhir:v "3. How to take xeljanz" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "3. How to take xeljanz" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This medicine is provided to you and supervised by a specialised doctor who knows how to treat your condition. Always take this medicine exactly as your doctor has told you, the recommended dose should not be exceeded. Check with your doctor or pharmacist if you are not sure. Rheumatoid arthritis</p><p>The recommended dose is 5 mg twice a day. Psoriatic arthritis</p><p>The recommended dose is 5 mg twice a day. If you suffer from rheumatoid arthritis or psoriatic arthritis, your doctor may switch your tablets between XELJANZ 5 mg film-coated tablets twice daily and XELJANZ 11 mg prolonged-release tablet once daily. You can start the XELJANZ prolonged-release tablet once daily or XELJANZ film-coated tablets twice daily on the day following the last dose of either tablet. You should not switch between XELJANZ film-coated tablets and XELJANZ prolonged-release tablet unless instructed by your doctor. Ankylosing spondylitis</p><p>The recommended dose is 5 mg twice a day.</p><p>Your doctor may decide to stop XELJANZ if XELJANZ does not work for you within 16 weeks. Ulcerative colitis</p><p>The recommended dose is 10 mg twice a day for 8 weeks, followed by 5 mg twice a day.</p><p>Your doctor may decide to extend the initial 10 mg twice a day treatment by an additional 8 weeks (16 weeks in total), followed by 5 mg twice a day.</p><p>Your doctor may decide to stop XELJANZ if XELJANZ does not work for you within 16 weeks.</p><p>For patients, who have previously taken biologic medicines to treat ulcerative colitis (such as those that block the activity of tumour necrosis factor in the body) and these medicines did not work, the doctor may decide to increase your dose of XELJANZ to 10 mg twice a day if you do not respond sufficiently to 5 mg twice a day. Your doctor will consider the potential risks, including that of developing blood clots in the lungs or veins, and potential benefits to you. Your doctor will tell you if this applies to you.</p><p>If your treatment is interrupted, your doctor may decide to restart your treatment. Use in children and adolescents Polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis</p><p>The recommended dose is 5 mg twice a day for patients 40 kg. Try to take your tablet at the same time every day (one tablet in the morning and one tablet in the evening). Tofacitinib tablets may be crushed and taken with water. Your doctor may reduce the dose if you have liver or kidney problems or if you are prescribed certain other medicines. Your doctor may also stop treatment temporarily or permanently if blood tests show low white blood cell or red blood cell counts. XELJANZ is for oral use. You can take XELJANZ with or without food. If you take more XELJANZ than you should If you take more tablets than you should, immediately tell your doctor or pharmacist. If you forget to take XELJANZ Do not take a double dose to make up for a forgotten tablet. Take your next tablet at the usual time and continue as before. If you stop taking XELJANZ You should not stop taking XELJANZ without discussing this with your doctor. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>" ] ] [ fhir:title [ fhir:v "4. Possible side effects" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "4. Possible side effects" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Some may be serious and need medical attention. Side effects in patients with polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis were consistent with those seen in adult rheumatoid arthritis patients with the exception of some infections (influenza, pharyngitis, sinusitis, viral infection) and gastrointestinal or general disorders (abdominal pain, nausea, vomiting, fever, headache, cough), which were more common in juvenile idiopathic arthritis paediatric population. Possible serious side effects In rare cases, infection may be life-threatening. Lung cancer, white blood cell cancer and heart attack have also been reported. If you notice any of the following serious side effects you need to tell a doctor straight away. Signs of serious infections (common) include</p><p>fever and chills</p><p>cough</p><p>skin blisters</p><p>stomach ache</p><p>persistent headaches Signs of ulcers or holes (perforations) in your stomach (uncommon) include</p><p>fever</p><p>stomach or abdominal pain</p><p>blood in the stool</p><p>unexplained changes in bowel habits Holes in stomach or intestines happen most often in people who also take nonsteroidal anti-inflammatory drugs or corticosteroids (e.g., prednisone). Signs of allergic reactions (unknown) include</p><p>chest tightness</p><p>wheezing</p><p>severe dizziness or light-headedness</p><p>swelling of the lips, tongue or throat</p><p>hives (itching or skin rash) Signs of blood clots in lungs or veins or eyes (uncommon: venous thromboembolism) include</p><p>sudden shortness of breath or difficulty breathing</p><p>chest pain or pain in upper back</p><p>swelling of the leg or arm</p><p>leg pain or tenderness</p><p>redness or discoloration in the leg or arm</p><p>acute changes in eyesight Signs of a heart attack (uncommon) include</p><p>severe chest pain or tightness (that may spread to arms, jaw, neck, back)</p><p>shortness of breath</p><p>cold sweat</p><p>light headedness or sudden dizziness Other side effects which have been observed with XELJANZ are listed below. Common (may affect up to 1 in 10 people): lung infection (pneumonia and bronchitis), shingles (herpes zoster), infections of nose, throat or the windpipe (nasopharyngitis), influenza, sinusitis, urinary bladder infection (cystitis), sore throat (pharyngitis), increased muscle enzymes in the blood (sign of muscle problems), stomach (belly) pain (which may be from inflammation of the stomach lining), vomiting, diarrhoea, feeling sick (nausea), indigestion, low white blood cell counts, low red blood cell count (anaemia), swelling of the feet and hands, headache, high blood pressure (hypertension), cough, rash, acne. Uncommon (may affect up to 1 in 100 people): lung cancer, tuberculosis, kidney infection, skin infection, herpes simplex or cold sores (oral herpes), blood creatinine increased (a possible sign of kidney problems), increased cholesterol (including increased LDL), fever, fatigue (tiredness), weight gain, dehydration, muscle strain, tendonitis, joint swelling, joint sprain, abnormal sensations, poor sleep, sinus congestion, shortness of breath or difficulty breathing, skin redness, itching, fatty liver, painful inflammation of small pockets in the lining of your intestine (diverticulitis), viral infections, viral infections affecting the gut, some types of skin cancers (non-melanoma-types). Rare (may affect up to 1 in 1,000 people): blood infection (sepsis), lymphoma (white blood cell cancer), disseminated tuberculosis involving bones and other organs, other unusual infections, joint infections, increased liver enzymes in the blood (sign of liver problems), pain in the muscles and joints. Very rare (may affect up to 1 in 10,000 people): tuberculosis involving the brain and spinal cord, meningitis, infection of the soft tissue and fascia. In general, fewer side effects were seen when XELJANZ was used alone than in combination with methotrexate in rheumatoid arthritis. Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>" ] ] [ fhir:title [ fhir:v "5. How to store xeljanz" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "5. How to store xeljanz" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the blister pack, bottle, or carton. The expiry date refers to the last day of that month. This medicine does not require any special temperature storage conditions. Store in the original package in order to protect from moisture. Do not use this medicine if you notice the tablets show visible signs of deterioration (for example, are broken or discoloured). Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>" ] ] [ fhir:title [ fhir:v "6. Contents of the pack and other information" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "6. Contents of the pack and other information" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><h2 id=\"what-xeljanz-contains-xeljanz-5-mg-film-coated-tablet\">What XELJANZ contains XELJANZ 5 mg film-coated tablet</h2><h2 id=\"the-active-substance-is-tofacitinib\">The active substance is tofacitinib.</h2><h2 id=\"each-5-mg-film-coated-tablet-contains-5-mg-of-tofacitinib-as-tofacitinib-citrate\">Each 5 mg film-coated tablet contains 5 mg of tofacitinib (as tofacitinib citrate).</h2><h2 id=\"the-other-ingredients-are-microcrystalline-cellulose-lactose-monohydrate-see-section-2-xeljanz-contains-lactose--croscarmellose-sodium-see-section-2-xeljanz-contains-sodium--magnesium-stearate-hypromellose-e464-titanium-dioxide-e171-macrogol-and-triacetin-xeljanz-10-mg-film-coated-tablet\">The other ingredients are microcrystalline cellulose, lactose monohydrate (see section 2 XELJANZ contains lactose ), croscarmellose sodium (see section 2 XELJANZ contains sodium ), magnesium stearate, hypromellose (E464), titanium dioxide (E171), macrogol, and triacetin. XELJANZ 10 mg film-coated tablet</h2><h2 id=\"the-active-substance-is-tofacitinib-1\">The active substance is tofacitinib.</h2><h2 id=\"each-10-mg-film-coated-tablet-contains-10-mg-of-tofacitinib-as-tofacitinib-citrate\">Each 10 mg film-coated tablet contains 10 mg of tofacitinib (as tofacitinib citrate).</h2><p>The other ingredients are microcrystalline cellulose, lactose monohydrate (see section 2 XELJANZ contains lactose ), croscarmellose sodium (see section 2 XELJANZ contains sodium ), magnesium stearate, hypromellose (E464), titanium dioxide (E171), macrogol, triacetin, FD&C Blue #2/Indigo Carmine Aluminum Lake (E132), and FD&C Blue #1/Brilliant Blue FCF Aluminum Lake (E133). What XELJANZ looks like and contents of the pack XELJANZ 5 mg film-coated tablets XELJANZ 5 mg film-coated tablet is white and round in appearance. The tablets are provided in blisters containing 14 tablets. Each pack contains 56, 112, or 182 tablets and each bottle contains 60 or 180 tablets. XELJANZ 10 mg film-coated tablets XELJANZ 10 mg film-coated tablet is blue and round in appearance. The tablets are provided in blisters containing 14 tablets. Each pack contains 56, 112, or 182 tablets and each bottle contains 60 or 180 tablets. Not all pack sizes may be marketed. Marketing Authorisation Holder Pfizer Europe MA EEIG Boulevard de la Plaine 1050 Bruxelles Belgium Manufacturer Pfizer Manufacturing Deutschland GmbH Betriebsst tte Freiburg Mooswaldallee 1 79090 Freiburg Germany For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: Belgi /Belgique / Belgien Luxembourg/Luxemburg Lietuva Belgi /Belgique / Belgien Pfizer Luxembourg SARL filialas Lietuvoje Pfizer S.A./N.V. Tel. +3705 2514T l/Tel: +32 (0)2 554 62 Luxembourg/Luxemburg Pfizer S.A. T l/Tel: +32 (0)2 554 62<br/>Magyarorsz g ,<br/>Pfizer Kft. .: +359 2 970 4Tel.: +36 1 488 37 esk republika Malta Pfizer, spol. s r.o. Vivian Corporation Ltd. Tel: +420 283 004 Tel: +35621 344Danmark Nederland Pfizer ApS Pfizer bv Tlf: +45 44 20 11 Tel: +31 (0)10 406 43 Deutschland Norge Pfizer Pharma GmbH Pfizer AS Tel: +49 (0)30 550055-51Tlf: +47 67 52 61 Eesti sterreich Pfizer Luxembourg SARL Eesti filiaal Pfizer Corporation Austria Ges.m.b.H. Tel: +372 666 7Tel: +43 (0)1 521 15-0</p><p>Polska PFIZER A.E. Pfizer Polska Sp. z o.o., .: +30 210 67 85 Tel.: +48 22 335 61 Espa a Portugal Pfizer, S.L. Laborat rios Pfizer, Lda. Tel: +34 91 490 99 Tel: +351 21 423 5France Rom nia Pfizer Pfizer Romania S.R.L. T l: +33 (0)1 58 07 34 Tel: +40 21 207 28 Hrvatska Slovenija Pfizer Croatia d.o.o. Pfizer Luxembourg SARL Tel: +385 1 3908 Pfizer, podru nica za svetovanje s podro ja farmacevtske dejavnosti, Ljubljana Tel.: +386 (0) 1 52 11 Ireland Slovensk republika Pfizer Healthcare Ireland Pfizer Luxembourg SARL, organiza n zlo ka Tel: 1800 633 363 (toll free) Tel: +421-2-3355 5+44 (0)1304 616 sland Suomi/Finland Icepharma hf. Pfizer Oy S mi: +354 540 8Puh/Tel: +358 (0)9 430 Italia Sverige Pfizer S.r.l. Pfizer AB Tel: +39 06 33 18 Tel: +46 (0)8 550 520<br/>United Kingdom (Northern Ireland) PFIZER . . (CYPRUS BRANCH) Pfizer Limited : +357 22 817Tel: +44 (0)1304 616Latvija Pfizer Luxembourg SARL fili le Latvij Tel.: +371 670 35 This leaflet was last revised in Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>" ] ] ) ] ) . # <MedicinalProductDefinition/mp008c725c88c429f9cddb37027a290218> a fhir:MedicinalProductDefinition ; fhir:id [ fhir:v "mp008c725c88c429f9cddb37027a290218"] ; # fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"^^xsd:anyURI ; fhir:link <http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi> ] ) ] ; # fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mp008c725c88c429f9cddb37027a290218\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mp008c725c88c429f9cddb37027a290218</b></p><a name=\"mp008c725c88c429f9cddb37027a290218\"> </a><a name=\"hcmp008c725c88c429f9cddb37027a290218\"> </a><a name=\"mp008c725c88c429f9cddb37027a290218-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/17/1178/001</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: XELJANZ 5 mg film-coated tablets</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>" ] ; # fhir:identifier ( [ fhir:system [ fhir:v "http://ema.europa.eu/identifier"^^xsd:anyURI ] ; fhir:value [ fhir:v "EU/1/17/1178/001" ] ] ) ; # fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/medicinal-product-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "MedicinalProduct" ] ; fhir:display [ fhir:v "Medicinal Product" ] ] ) ] ; # fhir:domain [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/medicinal-product-domain"^^xsd:anyURI ] ; fhir:code [ fhir:v "Human" ] ; fhir:display [ fhir:v "Human use" ] ] ) ] ; # fhir:status [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/publication-status"^^xsd:anyURI ] ; fhir:code [ fhir:v "active" ] ; fhir:display [ fhir:v "active" ] ] ) ] ; # fhir:legalStatusOfSupply [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000072084" ] ; fhir:display [ fhir:v "Medicinal product subject to medical prescription" ] ] ) ] ; # fhir:name ( [ fhir:productName [ fhir:v "XELJANZ 5 mg film-coated tablets" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000001" ] ; fhir:display [ fhir:v "Full name" ] ] ) ] ; ( fhir:part [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000002" ] ; fhir:display [ fhir:v "Invented name part" ] ] ) ] ] [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000003" ] ; fhir:display [ fhir:v "Scientific name part" ] ] ) ] ] [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000004" ] ; fhir:display [ fhir:v "Strength part" ] ] ) ] ] [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000005" ] ; fhir:display [ fhir:v "Pharmaceutical dose form part" ] ] ) ] ] ) ; ( fhir:usage [ fhir:country [ ( fhir:coding [ fhir:system [ fhir:v "urn:iso:std:iso:3166"^^xsd:anyURI ] ; fhir:code [ fhir:v "EU" ] ; fhir:display [ fhir:v "EU" ] ] ) ] ; fhir:jurisdiction [ ( fhir:coding [ fhir:system [ fhir:v "urn:iso:std:iso:3166"^^xsd:anyURI ] ; fhir:code [ fhir:v "EU" ] ; fhir:display [ fhir:v "EU" ] ] ) ] ; fhir:language [ ( fhir:coding [ fhir:system [ fhir:v "urn:ietf:bcp:47"^^xsd:anyURI ] ; fhir:code [ fhir:v "en" ] ; fhir:display [ fhir:v "en" ] ] ) ] ] ) ] ) . #
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
